SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50111/002002
	Serial No.	09/602,775
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Neil Cashman et al.
	Filing Date	June 23, 2000
	Group	~~1640~~ 1648
(37 CFR §1.98(b))	IDS Filed	January 3, 2001

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
HW	5,773,572	06/30/98	Fishleigh et al.	—	—	
	5,846,533	12/08/98	Prusiner et al.	—	—	
	5,891,641	04/06/99	Prusiner et al.	—	—	
	5,750,361	05/12/98	Prusiner et al.	—	—	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
HW	WO 99/66956	12/29/99	PCT	—	—	
	WO 99/19360	4/22/99	PCT	—	—	
	WO 99/15651	04/01/99	PCT	—	—	Yes
	WO 98/37210	08/27/98	PCT	—	—	
	WO 97/10505	03/20/97	PCT	—	—	
	WO 97/45746	12/04/97	PCT	—	—	
	WO 93/23432	11/25/93	PCT	—	—	
	WO 93/11155	06/10/93	PCT	—	—	
	EP 0 861 900 A1	09/02/98	Europe	—	—	
	DE 197 41 607 A1	09/20/97	Germany	—	—	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

HW	Bolton et al., "Molecular Location of a Species-Specific Epitope on the Hamster Scrapie Agent Protein," *J. Virology* 65:3667-3675 (1991).
HW	DiMartino et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-Carrier Linked Synthetic Peptide Immunogens," *J. Molecular Recognition* 4:85-90 (1991).

EXAMINER [signature] DATE CONSIDERED 3/31/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50111/002002
	Serial No.	09/602,775
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Neil Cashman et al.
	Filing Date	June 23, 2000
	Group	~~1640~~ 1647
(37 CFR §1.98(b))	IDS Filed	January 3, 2001

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

MW	Harmeyer et al., "Synthetic Peptide Vaccines Yield Monoclonal Antibodies to Cellular and Pathological Prion Proteins of Ruminants," *J. of General Virology* 79:937-945 (1998).
✓	Korth et al., "Prion (PrP^{Sc}) -Specific Epitope Defined by a Monoclonal Antibody," *Nature* 390:74-77 (1997) .
	Schenk et al., "Immunization with Amyloid-β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse," *Nature* 400:173-177 (1999).
	St. George-Hyslop et al., "Antibody Clears Senile Plaques," *Nature* 400:116-117 (1999).

EXAMINER Mark Wine DATE CONSIDERED 3/31/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50111/002002
		Serial No.	09/602,775
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Cashman et al.
		Filing Date	June 23, 2000
		Group	~~1646~~ 1648
(37 C.F.R. §1.98(b))		Customer No.	21559
		IDS Filed	March 9, 2001

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

MW	a	Bolton et al., "Identification of a Protein That Purifies with the Scrapie Prion," *Science* 218:1309-1311 (1982).
	b	Brown et al., "Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans," *Transfusion* 39:1169-1178 (1999).
	c	Brown et al., "The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy," *Transfusion* 38:810-816 (1998).
	d	Cioni, "Oxygen and acrylamide quenching of protein phosphorescence: correlation with protein dynamics," *Biophysical Chemistry* 87:15-24 (2000).
	e	Cohen et al., "Pathologic Conformations of Prion Proteins," *Annu. Rev. Biochem.* 67:793-819 (1998).
	f	Donne et al., "Structure of the recombinant full-length hamster prion protein PrP(29-231): The N terminus is highly flexible," *Proc. Natl. Acad. Sci. USA* 94:13452-13457 (1997).
	g	Fischer et al., "Binding of disease-associated prion protein to plasminogen," *Nature* 408:479-483 (2000).
	h	Hornemann et al., "A scrapie-like unfolding intermediate of the prion protein domain PrP(121-231) induced by acidic pH," *Proc. Natl. Acad. Sci. USA* 95:6010-6014 (1998).
	i	Jackson et al., "Reversible Conversion of Monomeric Human Prion Protein Between Native and Fibrilogenic Conformations," *Science* 283:1935-1937 (1999).
	j	Kascsak et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," *Journal of Virology* 61:3688-3692 (1987).
	k	Korth et al., "Monoclonal Antibodies Specific for the Native, Disease-Associated Isoform of the Prion Protein," *Methods in Enzymology* 309:106-122 (1999).
	l	Korth et al., "Prion (PrP^{Sc})-specific epitope defined by a monoclonal antibody," *Nature* 390:74-77 (1997).
✓	m	Kondejewski et al., "Dissociation of Antimicrobial and Hemolytic Activities in Cyclic Peptide Diastereomers by Systematic Alterations in Amphipathicity," *J. Biol. Chem.* 274:13181-13192 (1999).

EXAMINER	DATE CONSIDERED
	9/1/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50111/002002
	Serial No.	09/602,775
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Cashman et al.
	Filing Date	June 23, 2000
	Group	~~1645~~ 1648
(37 C.F.R. §1.98(b))	Customer No.	21559
	IDS Filed	March 9, 2001

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

LW	McGaughey et al., "π-Stacking Interactions. Alive and Well in Proteins," *J. Biol. Chem.* 273:15458-15463 (1998).
	Pan et al., "Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins," *Proc. Natl. Acad. Sci. USA* 90:10962-10966 (1993).
	Pergami et al., "Semipreparative Chromatographic Method to Purify the Normal Cellular Isoform of the Prion Protein in Nondenatured Form," *Analytical Biochemistry* 236:63-73 (1996).
	Prusiner "Novel Proteinaceous Infectious Particles Cause Scrapie," *Science* 216:136-144 (1982).
	Prusiner "Prions," *Proc. Natl. Acad. Sci. USA* 95:13363-13383 (1998).
	Riek et al., "NMR structure of the mouse prion protein domain PrP(121-231)," *Nature* 382:180-182 (1996).
	Safar et al., "Eight prion strains have PrP^{Sc} molecules with different conformations," *Nature Medicine* 4:1157-1165 (1998).
	Swietnicki et al., "pH-dependent Stability and Conformation of the Recombinant Human Prion Protein PrP(90-231)," *Journal of Biological Chemistry* 272:27517-27520 (1997).
	Williamson et al., "Mapping the Prion Protein Using Recombinant Antibodies," *Journal of Virology* 72:9413-9418 (1998).
	Zahn et al., "NMR solution structure of the human prion protein," *Proc. Natl. Acad. Sci. USA* 97:145-150 (2000).

EXAMINER [signature] DATE CONSIDERED 4/1/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50111/002002
	Serial No.	09/602,775
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Neil Cashman et al.
	Filing Date	June 23, 2000
	Group	1648
(37 C.F.R. § 1.98(b))	IDS Filed	February 6, 2003

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
MW	6,290,954	9/18/01	Prusiner et al.	—	—	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
MW	EP 1 213 301 A2	12.06.02	EPO	—	—	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

EXAMINER	Mark Wax	DATE CONSIDERED	4/1/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.